- Home
- MGNX vs SRV Comparison
MGNX vs SRV Comparison
Compare MGNX & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- SRV
- Stock Information
- Founded
- MGNX 2000
- SRV 2007
- Country
- MGNX United States
- SRV United States
- Employees
- MGNX N/A
- SRV N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- SRV Finance Companies
- Sector
- MGNX Health Care
- SRV Finance
- Exchange
- MGNX Nasdaq
- SRV Nasdaq
- Market Cap
- MGNX 151.9M
- SRV 130.8M
- IPO Year
- MGNX 2013
- SRV N/A
- Fundamental
- Price
- MGNX $2.20
- SRV $43.05
- Analyst Decision
- MGNX Hold
- SRV
- Analyst Count
- MGNX 10
- SRV 0
- Target Price
- MGNX $7.17
- SRV N/A
- AVG Volume (30 Days)
- MGNX 551.0K
- SRV 33.9K
- Earning Date
- MGNX 05-08-2025
- SRV 01-01-0001
- Dividend Yield
- MGNX N/A
- SRV 13.38%
- EPS Growth
- MGNX N/A
- SRV N/A
- EPS
- MGNX N/A
- SRV N/A
- Revenue
- MGNX $141,329,000.00
- SRV N/A
- Revenue This Year
- MGNX $177.84
- SRV N/A
- Revenue Next Year
- MGNX N/A
- SRV N/A
- P/E Ratio
- MGNX N/A
- SRV N/A
- Revenue Growth
- MGNX 16.68
- SRV N/A
- 52 Week Low
- MGNX $2.15
- SRV $30.73
- 52 Week High
- MGNX $19.54
- SRV $44.30
- Technical
- Relative Strength Index (RSI)
- MGNX 35.93
- SRV 41.79
- Support Level
- MGNX $2.16
- SRV $40.28
- Resistance Level
- MGNX $2.49
- SRV $45.18
- Average True Range (ATR)
- MGNX 0.17
- SRV 1.40
- MACD
- MGNX -0.00
- SRV -0.08
- Stochastic Oscillator
- MGNX 7.87
- SRV 50.18
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.